HR Execs on the Move


 
Sema4 is a rapidly growing patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.sema4.com
  • 333 Ludlow Street North Tower, 8th floor
    Stamford, CT USA 06902
  • Phone: 800.298.6470

Executives

Name Title Contact Details
Richard Miao
Interim Chief Financial Officer Profile
Eric Schadt
Founder, President, and Chief Research and Development Officer Profile
Samantha Violante
Chief of Staff Profile
Annette Gabriel
Vice President, Human Resources Profile
Vicky Louit
Vice President, Product Marketing Profile

Similar Companies

Abgent

Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inspirion Biosciences

Inspirion Biosciences protects the advancement of science, the safety and security of researchers, and the health of surrounding communities through integrated solutions in risk strategy. Learn more here.

EnviroLogix

Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.

ArrePath

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

Stoke Therapeutics

Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe #geneticdiseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. At Stoke, we believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or #TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. We have identified approximately 2,900 genetic diseases which we believe may be amenable to TANGO. At Stoke, we are united around a common goal: to improve the lives of people living with severe genetic diseases. Stoke is located in Bedford, MA with offices in Cambridge, MA.